Biopharma Patents Could Be Compromised Under Update Legislation

Partner Celine Jimenez Crowson is quoted in a Bloomberg Law article discussing an update to legislation that could impact existing pharma and biotech patents.

A proposed update to patent law could bring unintended consequences, including the invalidation of numerous pharma and biotech patents, according to Paul R. Michel, former chief judge of the U.S. Court of Appeals for the Federal Circuit.

Read More (Subscription Required): Biopharma Patents Could Be Compromised Under Update Legislation


Share Back To Listing
Loading data